帕妥珠单抗与曲妥珠单抗联合化疗在早期乳腺癌新辅助治疗中的疗效评价

doi:10.3877/cma.j.issn.1674-0785.2020.05.005

中华临床医师杂志(电子版) ›› 2020, Vol. 14 ›› Issue (05) : 344 -348. doi: 10.3877/cma.j.issn.1674-0785.2020.05.005

所属专题：乳腺疾病；文献；

乳腺癌·临床研究

帕妥珠单抗与曲妥珠单抗联合化疗在早期乳腺癌新辅助治疗中的疗效评价

程元甲¹, 徐玲¹, 叶京明¹, 张虹², 张爽², 刘荫华¹, 李宗翰¹^,^†(

)

^1. 100034　北京大学第一医院乳腺疾病中心
^2. 100034　北京大学第一医院病理科

收稿日期:2020-02-04 出版日期:2020-05-15
通信作者: 李宗翰
基金资助:
国家重点研发计划(2016YFC0901302); 北京医学奖励基金会基金项目(YXJL-2016-0040-0065)

Therapeutic effects of chemotherapy combined with pertuzumab and trastuzumab in neoadjuvant treatment of early breast cancer

Yuanjia Cheng¹, Ling Xu¹, Jingming Ye¹, Hong Zhang², Shuang Zhang², Yinhua Liu¹, Zonghan Li¹^,^†()

^1. Breast Disease Center, Peking University First Hospital, Beijing 100034, China
^2. Department of Pathology, Peking University First Hospital, Beijing 100034, China

Received:2020-02-04 Published:2020-05-15
Corresponding author: Zonghan Li
About author:
Corresponding author: Li Zonghan, Email: lzhan0315@163.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

程元甲, 徐玲, 叶京明, 张虹, 张爽, 刘荫华, 李宗翰. 帕妥珠单抗与曲妥珠单抗联合化疗在早期乳腺癌新辅助治疗中的疗效评价[J/OL]. 中华临床医师杂志(电子版), 2020, 14(05): 344-348.

Yuanjia Cheng, Ling Xu, Jingming Ye, Hong Zhang, Shuang Zhang, Yinhua Liu, Zonghan Li. Therapeutic effects of chemotherapy combined with pertuzumab and trastuzumab in neoadjuvant treatment of early breast cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(05): 344-348.

目的

探讨人表皮生长因子受体2（HER-2）阳性早期乳腺癌患者采用曲妥珠单抗（H）＋帕妥珠单抗（P）联合多西他赛（T）＋卡铂(C），即TCHP方案新辅助治疗的临床疗效。

方法

回顾性分析2019年3月至2019年12月北京大学第一医院乳腺疾病中心接受TCHP方案新辅助治疗并完成手术的HER-2阳性乳腺癌患者的临床资料。新辅助治疗期间利用MRI行临床疗效评价，手术后病理采用Miler-Payne标准评价。分析TCHP方案在HER-2阳性乳腺癌患者中的疗效。

结果

10例HER-2阳性患者符合入组标准，均为女性，中位年龄48岁。初始TCHP方案9例，TCH方案1周期后因帕妥珠单抗临床可及更改为TCHP方案1例。病理完全缓解率（pCR/G5）80.0%（8/10），未出现影响治疗的严重不良反应。

结论

TCHP方案是HER-2阳性乳腺癌患者有效的新辅助治疗方案，不良反应可控。

关键词: 乳腺肿瘤, 受体，表皮生长因子, 靶向治疗, 帕妥珠单抗

Objective

To investigate the clinical effects of docetaxel (T)+ carboplatin (C) combined with trastuzumab (H)+ pertuzumab (P) in the treatment of human epidermal growth factor receptor-2 (HER-2) positive early breast cancer.

Methods

From March 2019 to December 2019, the clinical data of HER-2 positive breast cancer patients who received new adjuvant treatment of TCHP and underwent surgery at the Breast Disease Center of Peking University First Hospital were analyzed retrospectively. During the neoadjuvant treatment, magnetic resonance imaging was used to evaluate the clinical effects, and the Miler-Payne grading system was used to evaluate the postoperative pathology. The clinical effects of TCHP in HER-2 positive breast cancer patients were analyzed.

Results

A total of 10 HER-2 positive patients were enrolled in this study. All of them were female, with a median age of 48 years old. There were nine cases who received TCHP treatment initially, and one case was switched to the TCHP regimen after the first cycle of TCH treatment. The pathologic complete response rate was 80% (8/10).

Conclusion

TCHP is an effective new adjuvant therapy for HER-2 positive breast cancer patients, with controllable side effects.

Key words: Breast neoplasms, Receptor, epidermal growth factor, Targeted therapy, Pertuzumab

表1 10例HER-2阳性乳腺癌患者的临床病理特征

项目		例数	百分比（%）
年龄（岁）		?	?
?	<30	1	10.0
?	30~<40	1	10.0
?	40~<50	4	40.0
?	50~<60	2	20.0
?	60~<70	2	20.0
月经状态		?	?
?	绝经前	6	60.0
?	绝经后	4	40.0
肿瘤分期		?	?
?	T1	1	10.0
?	T2	7	70.0
?	T3	2	20.0
淋巴结状态		?	?
?	N0	2	20.0
?	N1+N1mi	6	60.0
?	N2	2	20.0
?	N3	0	0.0
分子分型		?	?
?	Luminal B（HER-2阳性）型	4	40.0
?	HER-2阳性型	6	60.0
组织学分级		?	?
?	G1	0	0
?	G2	4	40.0
?	G3	6	60.0

表1 10例HER-2阳性乳腺癌患者的临床病理特征

项目		例数	百分比（%）
年龄（岁）		?	?
?	<30	1	10.0
?	30~<40	1	10.0
?	40~<50	4	40.0
?	50~<60	2	20.0
?	60~<70	2	20.0
月经状态		?	?
?	绝经前	6	60.0
?	绝经后	4	40.0
肿瘤分期		?	?
?	T1	1	10.0
?	T2	7	70.0
?	T3	2	20.0
淋巴结状态		?	?
?	N0	2	20.0
?	N1+N1mi	6	60.0
?	N2	2	20.0
?	N3	0	0.0
分子分型		?	?
?	Luminal B（HER-2阳性）型	4	40.0
?	HER-2阳性型	6	60.0
组织学分级		?	?
?	G1	0	0
?	G2	4	40.0
?	G3	6	60.0

表2 10例HER-2阳性乳腺癌患者新辅助治疗期间不良反应情况

不良反应	1级（例）	2级（例）	3级（例）	百分比（%）
恶心	4	1	1	60
呕吐	4	0	1	50
厌食	2	1	1	40
味觉改变	5	1	0	60
视力下降	1	0	0	10
失眠	4	0	0	40
疲劳乏力	8	1	0	90
肌痛	3	1	0	40
骨痛	4	1	0	50
腹泻	5	3	0	80
便秘	3	2	0	50
口腔溃疡	1	0	0	10
手足麻木	1	2	0	30
心悸	1	0	0	10
骨髓抑制	0	2	1	30

表2 10例HER-2阳性乳腺癌患者新辅助治疗期间不良反应情况

不良反应	1级（例）	2级（例）	3级（例）	百分比（%）
恶心	4	1	1	60
呕吐	4	0	1	50
厌食	2	1	1	40
味觉改变	5	1	0	60
视力下降	1	0	0	10
失眠	4	0	0	40
疲劳乏力	8	1	0	90
肌痛	3	1	0	40
骨痛	4	1	0	50
腹泻	5	3	0	80
便秘	3	2	0	50
口腔溃疡	1	0	0	10
手足麻木	1	2	0	30
心悸	1	0	0	10
骨髓抑制	0	2	1	30

1	Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol, 2010, 28(16): 2784-2795.
2	Wolff AC, Hammond M, Allison KH, et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary [J]. J Oncol Pract, 2018, 14(7): 437-441.
3	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
4	Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003, 12(5): 320-327.
5	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1): 7-34.
6	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
7	Network NCC. Breast Cancer [M]. Version 3ed. America, National Comprehensive Cancer Network® (NCCN®), 2019: 57
8	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2019 [M]. 北京：人民卫生出版社, 2019.
9	徐玲，叶京明，朱赛楠, 等. HER-2阳性早期乳腺癌TCH方案新辅助治疗疗效分析[J].中华医学杂志, 2018, 98(12): 907-911.
10	Ling X, Jingming Y, Sainan Z, et al. Analysis of neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in HER-2-positive breast cancer [J]. Natl Med J China, 2018, 98(12): 907-911.
11	Escrivá-de-Romaní S, Arumí M, Bellet M, et al. HER2-positive breast cancer: Current and new therapeutic strategies [J]. Breast, 2018, 39: 80-88.
12	Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J]. Lancet Oncol, 2012, 13(1): 25-32.
13	Shao Z, Pang D, Yang H, et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial [J]. JAMA Oncol, 2019. DOI: 10.1001/jamaoncol.2019.3692.
14	Chen S, Liang Y, Feng Z, et al. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis [J]. BMC Cancer, 2019, 19(1): 973.
15	Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) [J]. Ann Oncol, 2013, 24(9): 2278-2284.
16	Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study [J]. J Clin Oncol, 2019, 37(25): 2206-2216.

[1]	李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2]	河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3]	刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4]	张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5]	邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6]	程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7]	涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8]	朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9]	周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11]	韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12]	张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13]	王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14]	赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15]	陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Therapeutic effects of chemotherapy combined with pertuzumab and trastuzumab in neoadjuvant treatment of early breast cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Therapeutic effects of chemotherapy combined with pertuzumab and trastuzumab in neoadjuvant treatment of early breast cancer